

Product Name: Voreloxin Revision Date: 01/10/2021

# **Product Data Sheet**

## **Voreloxin**

**Cat. No.:** A3924

CAS No.: 175414-77-4

Formula: C18H19N5O4S


**M.Wt:** 401.44

Synonyms: SNS-595; Vosaroxin; AG 7352

Target: DNA Damage/DNA Repair

Pathway: Topoisomerase

Storage: Store at -20°C



# Solvent & Solubility

insoluble in H2O; insoluble in EtOH; insoluble in DMSO

In Vitro

Preparing Stock Solutions	Solvent  Concentration	1mg	5mg	10mg
	1 mM	2.4910 mL	12.4552 mL	24.9103 mL
	5 mM	0.4982 mL	2.4910 mL	4.9821 mL
	10 mM	0.2491 mL	1.2455 mL	2.4910 mL

Please refer to the solubility information to select the appropriate solvent.

# **Biological Activity**

Shortsummary	Topo II inhibitor	Topo II inhibitor		
IC <sub>50</sub> & Target				
In Vitro	Cell Viability Assay			
	Cell Line:	SK-BR-3, ScaBER, PANC-1, KB, HCT116, SKOV3, GT3TKB, Hs746T, Calu-6,		
		NCI-H460, PA-1, MES-SA, SBC-3, SBC-3/ETP and PC-14 cells		
	Preparation method:	The solubility of this compound in DMSO is >10 mM. General tips for obtaining		
		a higher concentration: Please warm the tube at 37°C for 10 minutes and/or		
		shake it in the ultrasonic bath for a while. Stock solution can be stored below		
		-20°C for several months.		

	Reacting conditions:	0.04 ~ 1.155 μM; 72 hrs
	Applications:	Voreloxin exhibited broad anti-proliferative activity in 15 cell lines, including 4
		drug-resistant lines, with the IC50 values ranging from 0.04 to 1.155 μM.
	Animal experiment	
In Vivo	Animal models:	Mice implanted with P388 leukemia cells
	Dosage form:	3.13, 12.5 or 50 mg/kg; i.p.; on days 1 and 5 after tumor implantation
	Applications:	In mice implanted with P388 leukemia cells, Voreloxin (50 mg/kg, i.p.) showed potent antitumor activity.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility masslightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

### **Product Citations**

See more customer validations on www.apexbt.com.

### References

- [1]. Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Cancer Chemother Pharmacol. 2009;64(1):53-65.
- [2]. Tsuzuki Y, Tomita K, Shibamori K, Sato Y, Kashimoto S, Chiba K. Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. Part 2. J Med Chem. 2004;47(8):2097-109.

### Caution

#### FOR RESEARCH PURPOSES ONLY.

#### NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

### **APExBIO Technology**

#### www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.
Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com













APE BIO



APE BIO